Rapidity of onset of response to Adalimumab in luminal Crohn's disease. RAPIDA study.
Phase of Trial: Phase IV
Latest Information Update: 07 Mar 2018
Price : $35 *
At a glance
- Drugs Adalimumab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms RAPIDA
- Sponsors AbbVie
- 31 Aug 2018 Biomarkers information updated
- 01 Nov 2017 Results evaluating the rapidity of onset of clinical response to ADA therapy presented at the 25th United European Gastroenterology Week
- 02 Feb 2017 Status changed from active, no longer recruiting to completed.